Cogent Biosciences (COGT) Profit After Tax (2017 - 2026)

Cogent Biosciences' Profit After Tax history runs 10 years deep, the most recent figure standing at -$97.4 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 35.3% year-over-year to -$97.4 million; the TTM figure through Mar 2026 stood at -$354.4 million (down 68.42% YoY), while the FY2025 annual figure was -$328.9 million, down 28.55% from the prior year.
• Profit After Tax was -$97.4 million for Q1 2026 at Cogent Biosciences, up from -$102.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$8.5 million in Q1 2023 to a low of -$102.5 million in Q4 2025.
• Historically, Profit After Tax has averaged -$52.1 million across 5 years, with a median of -$58.3 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Profit After Tax jumped 74.14% in 2023, then plunged 1061.08% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$39.6 million in 2022, then surged by 77.2% to -$9.0 million in 2023, then gained by 2.25% to -$8.8 million in 2024, then slumped by 1061.08% to -$102.5 million in 2025, then grew by 4.98% to -$97.4 million in 2026.
• The last three Profit After Tax figures came in at -$97.4 million (Q1 2026), -$102.5 million (Q4 2025), and -$80.9 million (Q3 2025), per Business Quant data.